Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

Related Keywords

Canada ,Vancouver ,British Columbia ,Netherlands ,United Kingdom ,Canadian ,British ,Christopherj Moreau , ,Company Or Algernon ,Algernon Pharmaceuticals ,Algernon Pharmaceuticals Inc ,Centre For Human Drug Research ,Company Phase ,Algernon Neuroscience ,Stroke Study ,Human Drug Research ,Idmt ,Stroke ,Clinical Trial Design ,Research Program ,Algernon ,